However, the therapeutic promise of MAbs has taken some time to be realized requiring humanization of mouse antibodies, recombinant production protocols, and discovery of ideal targets. Most of the approved MAbs are IgG1 molecules that can initiate complement-mediated cytotoxicity and antibody-dependent...
While tumour cell death can result in response to therapy, the selection, growth and dissemination of resistant cells can ultimately be fatal. In this Review, we present the main apoptosis pathways and other signalling pathways that interact with them, and discuss actionable molecular targets, ...
Lapatinib is an oral small-molecule TKI that targets both epidermal growth factor receptor (EGFR; HER1) and HER2 [39]. It has shown activity in preclinical studies in HER2-amplified GC [40]. The randomized phase III TRIO-013/Logic trial showed no significant improvement in OS with the addit...
Lapatinib is an oral small-molecule TKI that targets both epidermal growth factor receptor (EGFR; HER1) and HER2 [39]. It has shown activity in preclinical studies in HER2-amplified GC [40]. The randomized phase III TRIO-013/Logic trial showed no significant improvement in OS with the addit...
Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug. Targets 18, 171–176 (2018). Article CAS PubMed Google Scholar Alberts, P., Tilgase, A., Rasa, A., Bandere, K. & Venskus, D. The advent of oncolytic virotherapy in oncology...
Figure 1.(a) Genetic therapy involves the interaction between pharmacological molecules and the genetic material of the cell; (b) Targeted therapy involve specific sites to interact with molecular targets in the cell. BCR-ABL: Breakpoint Cluster Region-Abelson gene; nRTKi: Non-Receptor Tyrosine Ki...
Additionally, increased T lymphocyte infiltration and production of IFN-γ and IL-17 was observed. Importantly, F8.G7 therapy only targets the non-canonical VEGF pathway and the canonical pathway can still contribute to tumor angiogenesis. As concluded by these researchers, further research is ...
Moreover, to improve the targets and efficacy of treatments researchers are emphasizing on targeted therapy for TNBC. In this review, an effort has been made to focus on phenotypic and molecular variations in TNBC along with the role of conventional as well as newly identified pathways and ...
The identification of molecular targets and the growing knowledge of their cellular functions have led to the development of small molecule inhibitors as a major therapeutic class for cancer treatment. Both multitargeted and highly selective kinase inhibitors are used for the treatment of advanced treatm...
264RAD (AstraZeneca) is a human mAb that targets αvβ6 integrin that has a key role in activation of latent TGF-β, has been shown to reduce tumor growth and metastasis in vivo [108, 109]. Targeting αvβ6 with 264RAD antibody alone or combined with trastuzumab (Herceptin, Genentech)...